3Hand WL, Corwin RW, Steinberg TH, et al. Uptake of antibiotics by human alveolar macrophages. Am Rev Respir Dis, 1984, 129 (2) :933-940.
4Baldwin DR,Honeyboume D,Wise R. Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob Agents Chemother, 1992,36 (6) : 1175-1179.
5Conte PL,Potel G,Peltier P,et al. Lung distribution and pharmacokinetics of aerosolized Tobramycin. Am Rev Respir Dis, 1993, 147(8) : 1279-1282.
6Ragenar N, Karen L, Faulkner, et al. Differentiating meropenem and imipenem/cilastatin. Infect Dis Clin Pract, 1997,6 (2) : 291-296.
7Yu WL,Chuang YC,Jones RN.A pragmatic approach to identify extended-spectrum beta-lactamase-producing klebsiella pneumoniae in Taiwan:in vitro activity of newer and established antimicrobial agents.Diagn Microbiol Infect Dis,2004,48(4):277-282
8Gupta A,Della-Latta P,Todd B,et al.Outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit linked to artificial nails.Infect Control Hosp Epidemiol,2004,25(3):210-215
9Sturenburg E,Mack D.Extended-spectrum beta-lactamases:implications for the clinical microbiology laboratory,therapy,and infection control.J Infect,2003,47(4):273-295
10Lavigne JP,Bonnet R,Michaux-Charachon S,et al.Post-antibiotic and post-beta-lactamase inhibitor effects of ceftazidime plus sulbactam on extended-spectrum beta-lactamase-producing Gram-negative bacteria.J Antimicrob Chemother,2004,53(4):616-619
